Cart
sales@molnova.com
IDH2R140Q-IN-2
CAS No. 2749568-16-7
IDH2R140Q-IN-2( —— )
Catalog No. M37247 CAS No. 2749568-16-7
IDH2R140Q-IN-2 is an orally active and potent IDH2R140Q inhibitor with an IC50 of 29 nM.IDH2R140Q-IN-2 possesses potential antitumour activity, reducing D2HG production in TF-1 cell lines carrying the IDH2R140Q mutation (IC50 of 10 nM) and inhibiting tumour tissue D2HG levels.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 922 | In Stock |
|
| 10MG | 1121 | In Stock |
|
| 25MG | 1501 | In Stock |
|
| 50MG | 1841 | In Stock |
|
| 100MG | 2325 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameIDH2R140Q-IN-2
-
NoteResearch use only, not for human use.
-
Brief DescriptionIDH2R140Q-IN-2 is an orally active and potent IDH2R140Q inhibitor with an IC50 of 29 nM.IDH2R140Q-IN-2 possesses potential antitumour activity, reducing D2HG production in TF-1 cell lines carrying the IDH2R140Q mutation (IC50 of 10 nM) and inhibiting tumour tissue D2HG levels.
-
DescriptionIDH2R140Q-IN-2 (compound 36) is an an orally active IDH2R140Q inhibitor (IC50: 29 nM). IDH2R140Q-IN-2 reduces D2HG production in TF-1 cell lines expressing mutant IDH2R140Q (IC50: 10 nM). IDH2R140Q-IN-2 suppresses D2HG levels in tumor tissue. IDH2R140Q-IN-2 can be used for research of acute myeloid leukemia (AML).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMetabolic Enzyme/Protease
-
TargetDehydrogenase
-
RecptorDehydrogenase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2749568-16-7
-
Formula Weight484.4
-
Molecular FormulaC21H18F6N6O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESFC(F)(F)C=1C=CC=C(C1)NC=2N=C(N=C(N2)N3CCC(O)C3)NC4=CC=CC(=C4)C(F)(F)F
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Wei Q, et al. Structure-Based Drug Design of Novel Triaminotriazine Derivatives as Orally Bioavailable IDH2R140Q Inhibitors with High Selectivity and Reduced hERG Inhibitory Activity for the Treatment of Acute Myeloid Leukemia. J Med Chem. 2023 Sep 28;66(18):12894-12910.?
molnova catalog
related products
-
DHODH-IN-12
DHODH-IN-12 is a leflunomide derivative and a weak dihydrorotate dehydrogenase (DHODH) inhibitor with a pKa of 5.07.
-
G6PDi-1 B
G6PDi-1 is an effective G6PD inhibitor. It depletes NADPH and decreases inflammatory cytokine production.
-
AGI-14100
AGI-14100 is a novel and orally available mIDH1 inhibitor.AGI-14100 is used for the treatment of primary human myeloid leukemia.
